ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 132 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $56,949,000 | -39.1% | 2,026,656 | 0.0% | 0.26% | -31.2% |
| Q1 2022 | $93,510,000 | -47.5% | 2,026,656 | -4.3% | 0.38% | -26.3% |
| Q4 2021 | $178,063,000 | +26.1% | 2,118,284 | 0.0% | 0.51% | +32.6% |
| Q3 2021 | $141,162,000 | +10.6% | 2,118,284 | -11.7% | 0.39% | 0.0% |
| Q2 2021 | $127,642,000 | +22.6% | 2,399,284 | 0.0% | 0.39% | +24.8% |
| Q1 2021 | $104,105,000 | -33.4% | 2,399,284 | -20.3% | 0.31% | -27.9% |
| Q4 2020 | $156,406,000 | +7.7% | 3,011,284 | -32.2% | 0.43% | -18.1% |
| Q3 2020 | $145,251,000 | -31.9% | 4,443,284 | 0.0% | 0.52% | -43.1% |
| Q2 2020 | $213,366,000 | – | 4,443,284 | – | 0.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,426,095 | $111,940,000 | 6.63% |
| Paradigm Biocapital Advisors LP | 287,577 | $13,269,000 | 3.51% |
| Avidity Partners Management LP | 3,176,999 | $146,587,000 | 3.05% |
| Integral Health Asset Management, LLC | 215,000 | $9,920,000 | 2.58% |
| Matrix Capital Management Company, LP | 4,349,279 | $200,676,000 | 2.41% |
| Affinity Asset Advisors, LLC | 207,500 | $9,574,000 | 1.53% |
| Ikarian Capital, LLC | 202,203 | $9,329,000 | 1.23% |
| Ghost Tree Capital, LLC | 80,000 | $3,691,000 | 0.80% |
| Eventide Asset Management | 761,000 | $35,113,000 | 0.55% |
| Perceptive Advisors | 501,509 | $23,140,000 | 0.46% |